Skip to main content
TipRanks
Go Ultimate75% OFF

UnitedHealth (UNH) AI Stock Analysis

24,362 Followers
UNH

UnitedHealth

(NYSE:UNH)

Select Model
Rating:67Neutral
Price Target:$380.00â–²(14.98% Upside)
Action:downgraded
Date:11/19/26

UNH scores highest on financial quality and earnings-call fundamentals (strong absolute cash generation and reaffirmed long-term growth outlook with updated EPS guidance), but the overall score is held back by weakening recent trajectory (TTM revenue decline and margin compression) and clearly weak technicals with the stock trading below major moving averages. Valuation is supportive but not compelling enough to offset the bearish price trend and cost/margin risks highlighted on the call.

Positive Factors
Strong Cash GenerationUnitedHealth generates substantial operating and free cash flow, with free cash flow historically tracking earnings at roughly 82%-89%. This supports investment in care delivery, technology, and member services while providing capacity for dividends and other capital allocation over the next several quarters.
Negative Factors
Revenue and Margin CompressionThe recent contraction in revenue and profitability weakens the earnings base supporting future investment and capital returns. Margin compression also leaves less room to absorb medical-cost increases or reimbursement pressure, making a sustained recovery dependent on improved utilization and operating execution.

UnitedHealth Key Performance Indicators (KPIs)

Revenue by TypeCategorizes income by source, such as premiums, services, or products, revealing diversification and potential vulnerabilities in revenue streams.

$0.00$25.00B$50.00B$75.00B$100.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Products remain the primary growth engine, but recent momentum has broadened as Services continues a steady recovery rather than merely tracking enrollment. That mix is strategically encouraging: Medicare Advantage margin recovery, stronger Optum Health execution, and external Optum Rx membership can support more durable recurring revenue. Investment and Other remains volatile and should not be treated as a dependable contributor, leaving UnitedHealth’s outlook more dependent on operating businesses and their ability to offset elevated medical costs and commercial utilization pressure.

Data provided by:The Fly

UnitedHealth (UNH) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%40%UNH+6.34%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$296.12B
Dividend Yield
2.74%
Average Volume (3M)
5.72M
Price to Earnings (P/E)
18.9
Beta (1Y)
0.36
Revenue Growth
3.33%
EPS Growth
-8.75%
Country
US
Employees
390,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Plans

UnitedHealth Business Overview & Revenue Model

Company Description

UnitedHealth Group Incorporated (UNH) operates as a comprehensive healthcare enterprise across the United States, structuring its diverse services into four key divisions: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthc...

How the Company Makes Money

UnitedHealth primarily makes money through (1) health insurance and benefit administration and (2) health services, with revenue and earnings generated across its two main segments. 1) UnitedHealthcare (health benefits) - Premium revenue: A major sou...

UnitedHealth Earnings Call Summary

Earnings Call Date:Oct 13, 2026(Q3-2026)|% Change Since:-12.69%|Next Earnings Date:Jan 20, 2027
Earnings Call SentimentPositive

The call was predominantly positive, with improved third-quarter earnings, a lower medical care ratio, raised 2026 adjusted EPS guidance, Medicare Advantage margin recovery, strong Optum operating metrics, AI and modernization progress, capital returns, and confidence in 2027 growth. The main challenges were persistently high medical costs, commercial trends above 11%, negative Medicaid core margins, No Surprises Act arbitration costs, and continued policy and funding pressures.

Positive Updates

Strong Third-Quarter Financial Performance
Third-quarter 2026 revenue was $113 billion, and adjusted earnings per share was $4.69, up from $2.92 a year ago. The consolidated medical care ratio improved to 88.4% from 89.9% last year.

Negative Updates

Persistently High Healthcare Costs
Costs remain stubbornly high across the healthcare landscape, particularly in specialty pharmacy and acute healthcare service intensity. Management also said care intensity remains elevated relative to historical norms and that clinician pricing pressure continues.

Company Guidance

UnitedHealth Group reaffirmed its 13%-16% long-term target growth range, views the lower end of its long-term 13%-16% growth rate as a more reasonable starting point for 2027, and updated 2026 adjusted EPS guidance to at least $20.50; it expects debt-to-cap ratio to approach 40% by year-end, dividends to exceed $8 billion by year-end, 2026 core Medicaid margins to be moderately better than negative 1%, and 2026 Medicare margins to be near the top end of the 2%-4% range. For 2027, more than 94% of Medicare-eligible individuals nationwide will have access to a UnitedHealthcare Medicare plan, approximately 90% will have access to a Medicare Advantage plan with a $0 premium option, chronic special needs plans will be available to nearly 50 million Medicare-eligible individuals, and the company expects to approach 75% of total members in four-plus Star plans compared to the industry average of 70%; Optum Health remains paced toward its 6%-8% target margin range by 2028, while Optum Insight expects meaningful progress in 2027, setting the foundation for accelerating growth in 2028 and beyond.

UnitedHealth Financial Statement Overview

Summary

Strong overall fundamentals supported by robust operating cash flow ($26.2B TTM) and free cash flow ($22.8B TTM) plus a large equity base (~$104B TTM) and solid ROE (~22% TTM). Offsetting this strength are a TTM revenue decline (-10.4%) and notable margin compression (net margin ~3.5% TTM vs ~6% in 2022–2023), alongside meaningful leverage (~$74B debt).

Income Statement

74Positive

Balance Sheet

72Positive

Cash Flow

78Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue449.66B447.57B400.28B371.62B324.16B287.60B
Gross Profit102.58B82.92B89.40B90.96B79.62B69.65B
EBITDA27.99B23.06B28.08B36.33B31.84B27.07B
Net Income15.88B12.06B14.40B22.38B20.12B17.29B
Balance Sheet
Total Assets312.78B309.58B298.28B273.72B245.71B212.21B
Cash, Cash Equivalents and Short-Term Investments28.55B28.12B29.11B29.63B27.91B23.91B
Total Debt74.33B78.39B76.90B67.44B57.62B46.00B
Total Liabilities207.24B207.88B195.69B174.80B159.36B135.73B
Stockholders Equity98.10B94.11B92.66B88.76B77.77B71.76B
Cash Flow
Free Cash Flow22.83B16.07B20.70B25.68B23.40B19.89B
Operating Cash Flow26.20B19.70B24.20B29.07B26.21B22.34B
Investing Cash Flow-11.43B-8.69B-20.53B-15.57B-28.48B-10.37B
Financing Cash Flow-16.06B-11.64B-3.51B-11.53B4.23B-7.46B

UnitedHealth Technical Analysis

Technical Analysis SentimentNegative
Last Price330.48

Price Trends

50DMA389.44Negative
100DMA398.52Negative
200DMA365.47Negative

Market Momentum

MACD-7.49Positive
RSI24.23Positive
STOCH8.52Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UNH, the sentiment is Negative. The current price of 330.48 is below the 20-day moving average (MA) of 398.43, below the 50-day MA of 389.44, and below the 200-day MA of 365.47, indicating a bearish trend. The MACD of -7.49 indicates Positive momentum. The RSI at 24.23 is Positive, neither overbought nor oversold. The STOCH value of 8.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UNH.

UnitedHealth Risk Analysis

UnitedHealth disclosed 21 risk factors in its most recent earnings report. UnitedHealth reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

2 New Risks
1.Our increasing use of AI presents legal, regulatory and business risks to our operations, reputation and financial results.Q4, 2025
2.Our businesses are subject to risks associated with unfavorable economic conditions.Q4, 2023

UnitedHealth Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

UNH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ELVELV76Outperform$84.30B16.6211.59%1.76%3.60%-4.06%
CICI75Outperform$71.95B12.0214.10%2.27%6.79%-0.38%
CVSCVS71Outperform$102.41B9.2414.13%3.32%6.77%2114.64%
UNHUNH67Neutral$296.12B18.8616.35%2.74%3.33%-8.75%
CNCCNC66Neutral$32.47B22.166.78%―9.71%―
HUMHUM55Neutral$45.64B36.616.70%0.93%22.02%-3.07%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%UNHCNCCICVSHUMELVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
UNH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
UNHUnitedhealth Group Inc.330.4818.816.03%
CNCCentene65.5829.0879.67%
CICigna273.041.110.41%
CVSCVS Health Corp80.044.345.73%
HUMHumana380.00155.8369.51%
ELVElevance Health, Inc.390.1674.7023.68%

UnitedHealth Corporate Events

Executive/Board Changes

UnitedHealth Appoints Madeline Bell as Independent Director

Neutral
Nov 9, 2026

UnitedHealth Group announced on Nov. 9, 2026, the appointment of Madeline S. Bell as an independent director, effective Nov. 3, 2026. Bell was the former president and CEO of Children’s Hospital of Philadelphia, where she held a four-decade career an...

Business Operations and StrategyRegulatory Filings and Compliance

UnitedHealth to Present Strategy at Wells Fargo Conference

Neutral
Sep 8, 2026

UnitedHealth Group senior leaders will participate in an interview-style discussion at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 8:00 a.m. Eastern Time, addressing the company’s strategy, market positions,...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 19, 2026